Back to Search
Start Over
A Perspective of Immunotherapy for Prostate Cancer.
- Source :
- Cancers; Jul2016, Vol. 8 Issue 7, p64, 20p
- Publication Year :
- 2016
-
Abstract
- In cancer patients, the immune system is often altered with an excess of inhibitory factors, such as immunosuppressive cytokines, produced by regulatory T cells (Treg) or myeloid-derived suppressor cells (MDSC). The manipulation of the immune system has emerged as one of new promising therapies for cancer treatment, and also represents an attractive strategy to control prostate cancer (PCa). Therapeutic cancer vaccines and immune checkpoint inhibitors have been the most investigated in clinical trials. Many trials are ongoing to define the effects of immune therapy with established treatments: androgen deprivation therapy (ADT) and chemotherapy (CT) or radiotherapy (RT). This article discusses some of these approaches in the context of future treatments for PCa. [ABSTRACT FROM AUTHOR]
- Subjects :
- GRANULOCYTE-macrophage colony-stimulating factor
MACROPHAGES
PROSTATE tumors treatment
IPILIMUMAB
SIPULEUCEL-T (Drug)
CANCER chemotherapy
CELL lines
CYTOKINES
DENDRITIC cells
IMMUNE system
IMMUNOTHERAPY
LIGANDS (Biochemistry)
PROSTATE tumors
RADIOTHERAPY
RECOMBINANT proteins
T cells
TUMOR markers
VIRAL vaccines
GENETICS
THERAPEUTICS
PHYSIOLOGY
Subjects
Details
- Language :
- English
- ISSN :
- 20726694
- Volume :
- 8
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Cancers
- Publication Type :
- Academic Journal
- Accession number :
- 117408442
- Full Text :
- https://doi.org/10.3390/cancers8070064